EurekaMag.com logo
+ Site Statistics
References:
47,893,527
Abstracts:
28,296,643
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Rituximab for non-Hodgkin's lymphoma: a story of rapid success in translation


, : Rituximab for non-Hodgkin's lymphoma: a story of rapid success in translation. Clinical and Translational Science 7(1): 82-86

Translational stories range from straightforward to complex. In this commentary, the story of the rapid and successful translation of rituximab therapy for the treatment of non-Hodgkin's lymphoma (NHL) is examined. Development of this monoclonal antibody therapy began in the late 1980s. In 1994, rituximab received its first approval for the treatment of NHL by the United States Food and Drug Administration (FDA). Rituximab has since been approved for additional indications and has transformed medical practice. However, the social and political implications of these rapid successes are only beginning to become clear. In this commentary, key events in the rapid translation of rituximab from the bench to bedside are highlighted and placed into this historical framework. To accomplish this, the story of rituximab is divided into the following six topics, which we believe to be widely applicable to case studies of translation: (1) underlying disease, (2) key basic science, (3) key clinical studies in translation, (4) FDA approval process, (5) changes to medical practice, and (6) the social and political influences on translation.


Accession: 055589976

PMID: 24528902

DOI: 10.1111/cts.12111

Submit PDF Full Text: Here


Submit PDF Full Text

No spam - Every submission is manually reviewed

Due to poor quality, we do not accept files from Researchgate

Submitted PDF Full Texts will always be free for everyone
(We only charge for PDFs that we need to acquire)

Select a PDF file:
Close
Close

Related references

Saleh, M., 2003: Monoclonal antibody therapy of non-Hodgkin's lymphoma: the Rituximab story. The advent of monoclonal antibodies targeted at tumor associated or tumor specific antigens provides a novel approach for the treatment of a broad range of malignancies. Such targeting agents can either be used as unlabeled molecules to induced an...

Pfreundschuh, M.; Poeschel, V.; Zeynalova, S.; Hänel, M.; Held, G.; Schmitz, N.; Viardot, A.; Dreyling, M.H.; Hallek, M.; Mueller, C.; Wiesen, M.H.J.; Witzens-Harig, M.; Truemper, L.; Keller, U.; Rixecker, T.; Zwick, C.; Murawski, N., 2015: Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group. To study pharmacokinetics, toxicity, and efficacy of prolonged rituximab exposure in elderly patients with diffuse large B-cell lymphoma (DLBCL). In the SMARTE-R-CHOP-14 trial, rituximab 375 mg/m(2) was administered, together with six cycles of ri...

Palickova, M.; Mocikova, H.; Vernerova, Z.; Campr, V.; Kozak, T., 2014: BEACOPP escalated and rituximab in the treatment of Hodgkin lymphoma occurring concurrently with diffuse large B-cell non-Hodgkin lymphoma. Leukemia & Lymphoma 54(9): 2081-2082

Zhao, W.; Gao, Y.; Bai, B.; Cai, Q-Chun.; Wang, X-Xiao.; Cai, Q-Qing.; Huang, H-Qiang., 2015: Safety and efficacy of non-initial rapid infusion of rituximab plus chemotherapy in Chinese patients with CD20+ non-Hodgkin's lymphoma. To evaluate the safety and efficacy of rapid rituximab infusion (RRI) plus chemotherapy in patients with CD20(+) non-Hodgkin's lymphoma (NHL). A total of 177 patients received 4 - 6 cycles of rituximab-based chemotherapy. The first cycle was...

Provencio, M.; Sanchez, A.; Maximiano, C.; Cantos, B.; Méndez, M.; Bonilla, Félix., 2010: A prospective study of left ventricle function after treatment with rapid-infusion rituximab in patients with non-Hodgkin lymphoma. We designed a prospective study to measure the left ventricular ejection fraction of 42 patients with non-Hodgkin lymphoma treated with Rituximab-based chemotherapy in a 1-h infusion. Our patients were not selected on the basis of their cardiac st...

Schulz, H.; Rehwald, U.; Morschhauser, F.; Elter, T.; Driessen, C.; Rüdiger, T.; Borchmann, P.; Schnell, R.; Diehl, V.; Engert, A.; Reiser, M., 2007: Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Because nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) express CD20, rituximab may be used as a nonmutagenic treatment option to avoid late toxicities in this rather indolent entity. Between 1999 and 2004, the German Hodgkin Study Group (...

Schulz, H.; Rehwald, U.; Morschhauser, F.; Elter, T.; Driessen, C.; Ruediger, T.; Borchmann, P.; Schnell, R.; Diehl, V.; Engert, A.; Reiser, M., 2008: Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Because nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) express CD20, rituximab may be used as a nonmutagenic treatment option to avoid late toxicities in this rather indolent entity. Between 1999 and 2004, the German Hodgkin Study Group (...

Rehwald, U.; Schulz, H.; Reiser, M.; Sieber, M.; Staak, J.Oliver.; Morschhauser, F.; Driessen, C.; Rudiger, T.; Muller-Hermelink, K.; Diehl, V.; Engert, A., 2003: Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. This phase 2 trial was performed to evaluate the safety and efficacy of the chimeric monoclonal anti-CD20 antibody rituximab in patients with relapsed lymphocyte-predominant Hodgkin lymphoma or other CD20(+) subtypes of Hodgkin disease (HD). Eligi...

Lang, D.; George, C., 2011: Acute adverse reactions of rapid Rituximab infusion among adult patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Rapid Rituximab infusion has become increasingly popular globally. Although pharmaceutical manufacturers recommend second and subsequent infusions to run over 2-3 hours, many cancer centres have changed their clinical practice based on their own r...

Küllmer, A.; Herrmann, G.; Riecken, B., 2013: Rapid-progressive decrease of cognitive and physical functions in a B-cell non-Hodgkin's lymphoma patient treated with rituximab/bendamustine. A 71-year-old man with Richter's syndrome (transformation of chronic lymphocytic leukemia [CLL] to diffuse large B-cell lymphoma) was admitted to our hospital to get his second cycle of rituximab/bendamustin treatment. He had been diagnosed w...